Hexabrix is an ionic dimer contrast medium. Intravascular injection of Hexabrix enhances those vessels in the path of the flow, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. The contrast agent is transported through the circulatory system to the kidneys and is excreted unchanged in the urine. Hexabrix is used primarily for peripheral arteriography

The France-based Guerbet Group is highly specialized in contrast media for medical imaging. Its strategic goal is to be a key player in this market. Guerbet Group produces products for x-ray imaging, MRI, ultrasound imaging and imaging through radioactive tracers.

Ionic dimers are used as x-ray contrast agents. They are formed by joining 2 ionic monomers and eliminating 1 carboxyl group and contain 6 iodine atoms for every 2 particles in solution (CM ratio=3).
Ionic dimers have an intermediate osmolarity, intermediate viscosity and an intermediate hydrophilicity between that of ionic and nonionic monomers. The only commercially available ionic dimer is ioxaglate (Hexabrix). Ioxaglate is used primarily for peripheral arteriography.

Mallinckrodt, a Tyco Healthcare company makes and distributes products for respiratory care; bulk and dosage pharmaceuticals, primarily for pain relief and addiction therapy; and imaging agents for magnetic resonance, ultrasound, x-ray, and nuclear medicine applications. With worldwide manufacturing and distribution facilities, as well as worldwide sales offices, Mallinckrodt sells its products worldwide.

In June 2007 Tyco International Ltd. completed the separation of its healthcare business, which is named Covidien. Mallinckrodt, Inc. is now part of Covidien Ltd.